PubRank

Andrew K Godwin

Author PubWeight™ 256.78‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007 9.29
2 A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 2010 4.96
3 MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007 4.95
4 Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013 4.35
5 A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010 3.86
6 Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012 3.85
7 Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 2013 3.81
8 Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008 3.41
9 A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet 2011 3.37
10 Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med 2005 3.35
11 Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 2011 3.33
12 Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2015 3.00
13 Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol Cell 2003 2.90
14 Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 2009 2.85
15 Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012 2.71
16 AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004 2.67
17 Concern Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A 2003 2.52
18 Focus on epithelial ovarian cancer. Cancer Cell 2004 2.47
19 A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet 2012 2.45
20 Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 2013 2.39
21 Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 2009 2.37
22 Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res 2009 2.33
23 Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther 2003 2.27
24 Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet 2013 2.24
25 A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011 2.24
26 Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005 2.22
27 Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 2010 2.19
28 A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res 2010 2.15
29 Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2009 2.13
30 The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res 2011 2.09
31 Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2011 1.99
32 Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A 2008 1.97
33 PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res 2011 1.91
34 Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 2010 1.90
35 FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development 2010 1.86
36 Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 2009 1.84
37 19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res 2012 1.81
38 Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Phila) 2010 1.80
39 AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev 2007 1.75
40 Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 2010 1.75
41 Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res 2006 1.71
42 BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation. Cancer Res 2006 1.65
43 Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res 2011 1.65
44 Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 2009 1.61
45 Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biol Ther 2004 1.58
46 Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet 2010 1.56
47 LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 2010 1.55
48 Perception of differentiation cues by GATA factors in primitive endoderm lineage determination of mouse embryonic stem cells. Dev Biol 2005 1.49
49 Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res 2010 1.46
50 Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat 2002 1.44
51 Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk. Hum Mol Genet 2008 1.43
52 DNA array-based method for detection of large rearrangements in the BRCA1 gene. Genes Chromosomes Cancer 2002 1.41
53 BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast Cancer Res Treat 2008 1.40
54 Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res 2012 1.38
55 Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem 2002 1.36
56 A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007 1.36
57 Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience. Am J Med Genet C Semin Med Genet 2003 1.36
58 Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis. Cancer Res 2003 1.34
59 A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. Hum Mol Genet 2011 1.34
60 Novel glycan biomarkers for the detection of lung cancer. J Proteome Res 2011 1.33
61 Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 2006 1.32
62 Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data. Cancer Res 2009 1.31
63 Altered expression of the septin gene, SEPT9, in ovarian neoplasia. J Pathol 2003 1.31
64 Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res 2011 1.29
65 Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol 2007 1.28
66 Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis 2013 1.28
67 Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res 2005 1.26
68 Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat 2009 1.26
69 Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 2006 1.26
70 Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 2002 1.26
71 Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol 2007 1.24
72 Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol 2007 1.24
73 Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 2011 1.23
74 WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer 2005 1.22
75 Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res 2011 1.22
76 Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 2003 1.21
77 Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. Hum Mutat 2006 1.19
78 Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 2002 1.19
79 Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer 2011 1.18
80 Predisposition to cancer caused by genetic and functional defects of mammalian Atad5. PLoS Genet 2011 1.18
81 Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 2007 1.17
82 Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 2003 1.17
83 Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012 1.17
84 Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer 2002 1.16
85 The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res 2008 1.14
86 Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 2009 1.14
87 Biological significance of prolactin in gynecologic cancers. Cancer Res 2009 1.13
88 Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol 2011 1.12
89 Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res 2008 1.11
90 Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol Cancer Ther 2009 1.10
91 High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Genes Chromosomes Cancer 2009 1.10
92 Linking transcriptional elongation and messenger RNA export to metastatic breast cancers. Cancer Res 2005 1.09
93 Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer 2007 1.09
94 Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Genes Chromosomes Cancer 2012 1.08
95 An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. Nucleic Acids Res 2011 1.08
96 Ovarian normal and tumor-associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix-dependent manner. Gynecol Oncol 2008 1.07
97 BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 2006 1.07
98 Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. Gynecol Oncol 2006 1.06
99 ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor. PLoS One 2013 1.06
100 Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia. PLoS One 2009 1.05
101 Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk. J Natl Cancer Inst 2009 1.04
102 Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc Natl Acad Sci U S A 2013 1.04
103 Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res 2009 1.04
104 Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology. Lab Chip 2014 1.03
105 Loss of GATA6 leads to nuclear deformation and aneuploidy in ovarian cancer. Mol Cell Biol 2009 1.03
106 Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat 2014 1.03
107 Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. Cancer 2002 1.02
108 The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors. Cell Cycle 2008 1.02
109 White spot syndrome virus open reading frame 222 encodes a viral E3 ligase and mediates degradation of a host tumor suppressor via ubiquitination. J Virol 2006 1.01
110 Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2010 1.01
111 Clinical and molecular characteristics of gastrointestinal stromal tumors in the pediatric and young adult population. Curr Oncol Rep 2009 1.00
112 Loss of A-type lamin expression compromises nuclear envelope integrity in breast cancer. Chin J Cancer 2011 1.00
113 Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Mol Carcinog 2007 0.99
114 Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res 2014 0.99
115 Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat 2012 0.98
116 Serum antimüllerian hormone in healthy premenopausal women. Fertil Steril 2011 0.97
117 Nuclear entry of activated MAPK is restricted in primary ovarian and mammary epithelial cells. PLoS One 2010 0.97
118 Nuclear envelope structural defects cause chromosomal numerical instability and aneuploidy in ovarian cancer. BMC Med 2011 0.97
119 Enhanced counseling for women undergoing BRCA1/2 testing: impact on subsequent decision making about risk reduction behaviors. Health Educ Behav 2005 0.97
120 Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 2012 0.97
121 A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2012 0.97
122 An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. PLoS One 2012 0.96
123 The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2006 0.96
124 In vivo imaging and therapeutic treatments in an orthotopic mouse model of ovarian cancer. J Vis Exp 2010 0.95
125 The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene. Proc Natl Acad Sci U S A 2003 0.95
126 A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol 2011 0.95
127 Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling. Cancer Res 2010 0.94
128 Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer 2003 0.94
129 Identification of a second G-C-rich promoter conserved in the human, murine and rat tumor suppressor genes HIC1. Oncogene 2004 0.94
130 The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis 2005 0.94
131 ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med 2012 0.93
132 No increased risk of breast cancer associated with alcohol consumption among carriers of BRCA1 and BRCA2 mutations ages <50 years. Cancer Epidemiol Biomarkers Prev 2006 0.93
133 Perceived stress is associated with impaired T-cell response to HPV16 in women with cervical dysplasia. Ann Behav Med 2008 0.92
134 Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. Hum Mutat 2012 0.92
135 Involvement of RHO GTPases and ERK in synuclein-gamma enhanced cancer cell motility. Int J Oncol 2006 0.92
136 A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol 2011 0.91
137 Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biol Ther 2011 0.91
138 Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma. Breast Cancer Res 2012 0.91
139 Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells: molecular basis linking ovulation and cancer risk. Cancer Res 2004 0.91
140 A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2013 0.90
141 BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst 2015 0.90
142 Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2014 0.89
143 Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Hum Mol Genet 2011 0.89
144 Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/invasion. PLoS One 2011 0.89
145 Molecular research directions in the management of gastrointestinal stromal tumors. Curr Treat Options Oncol 2005 0.89
146 Proteome changes in ovarian epithelial cells derived from women with BRCA1 mutations and family histories of cancer. Mol Cell Proteomics 2004 0.89
147 A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012 0.89
148 Drug repurposing for gastrointestinal stromal tumor. Mol Cancer Ther 2013 0.89
149 Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. Breast Cancer Res 2012 0.88
150 Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012 0.88
151 Sequencing of candidate chromosome instability genes in endometrial cancers reveals somatic mutations in ESCO1, CHTF18, and MRE11A. PLoS One 2013 0.87
152 Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet 2011 0.87
153 Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. DNA Cell Biol 2002 0.87
154 The molecular pathogenesis of gastrointestinal stromal tumors. Clin Colorectal Cancer 2006 0.86
155 No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Res Treat 2008 0.84
156 Alteration of Differentiation Potentials by Modulating GATA Transcription Factors in Murine Embryonic Stem Cells. Stem Cells Int 2010 0.84
157 Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer cells. Oncogene 2005 0.83
158 Acculturative stress and inflammation among Chinese immigrant women. Psychosom Med 2014 0.82
159 Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res 2010 0.82
160 Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro. Mol Cancer 2009 0.81
161 BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance. Expert Rev Anticancer Ther 2006 0.81
162 Expression of Siglec-11 by human and chimpanzee ovarian stromal cells, with uniquely human ligands: implications for human ovarian physiology and pathology. Glycobiology 2011 0.81
163 Culturally appropriate education intervention on biospecimen research participation among Chinese Americans. Cancer Epidemiol Biomarkers Prev 2014 0.81
164 Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing. J Mol Diagn 2009 0.81
165 Role of gamma-synuclein in microtubule regulation. Exp Cell Res 2010 0.81
166 Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS One 2012 0.80
167 Anti-human embryonic stem cell monoclonal antibody Hesca-2 binds to a glycan epitope commonly found on carcinomas. Stem Cells Dev 2010 0.80
168 Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics 2008 0.80
169 Microarrays in cancer: research and applications. Biotechniques 2003 0.80
170 OVCA2 is downregulated and degraded during retinoid-induced apoptosis. Int J Cancer 2002 0.79
171 Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Res 2011 0.79
172 Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry. Breast Cancer Res 2011 0.79
173 Transcriptional regulation of hTREX84 in human cancer cells. PLoS One 2012 0.78
174 The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2012 0.78
175 Epimorphin-induced MET sensitizes ovarian cancer cells to platinum. PLoS One 2013 0.78
176 Ovca1, a candidate gene of the genetic modifier of Tp53, Mop2, affects mouse embryonic lethality. Genes Chromosomes Cancer 2008 0.77
177 Ras/MAPK pathway confers basement membrane dependence upon endoderm differentiation of embryonic carcinoma cells. J Biol Chem 2002 0.77
178 Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1. BMC Cancer 2014 0.76
179 Telomere length changes in human cancer. Methods Mol Med 2002 0.76
180 Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor. Expert Opin Investig Drugs 2015 0.75
181 Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst 2017 0.75
182 Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Res Treat 2012 0.75
183 Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. Clin Breast Cancer 2007 0.75
184 Mass spectrometric identification of serine hydrolase OVCA2 in the medulloblastoma cell line DAOY. Cancer Lett 2005 0.75